CenterBook Partners LP lessened its stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 54.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,944 shares of the company's stock after selling 93,646 shares during the period. CenterBook Partners LP owned 0.15% of CryoPort worth $1,356,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the company. State of Alaska Department of Revenue bought a new position in CryoPort during the third quarter valued at approximately $40,000. State of Wyoming bought a new stake in CryoPort in the 3rd quarter worth approximately $81,000. Highland Investment Advisors LLC bought a new stake in CryoPort in the 2nd quarter worth approximately $306,000. Counterpoint Mutual Funds LLC purchased a new stake in shares of CryoPort during the 3rd quarter worth approximately $324,000. Finally, Kerrisdale Advisers LLC purchased a new stake in shares of CryoPort during the 2nd quarter worth approximately $355,000. Hedge funds and other institutional investors own 92.90% of the company's stock.
CryoPort Stock Performance
NASDAQ:CYRX opened at $20.47 on Tuesday. The stock's fifty day moving average is $17.07 and its 200 day moving average is $13.51. CryoPort, Inc. has a fifty-two week low of $7.61 and a fifty-two week high of $20.57. The firm has a market capitalization of $1.04 billion, a PE ratio of -21.10 and a beta of 1.89.
CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%. The firm had revenue of $50.22 million for the quarter, compared to analysts' expectations of $48.66 million. Equities analysts forecast that CryoPort, Inc. will post -0.83 EPS for the current year.
Analyst Ratings Changes
Several brokerages recently weighed in on CYRX. Weiss Ratings upgraded shares of CryoPort from a "sell (d)" rating to a "hold (c-)" rating in a research report on Thursday, October 8th. Roth Capital reiterated a "buy" rating and set a $21.00 price objective on shares of CryoPort in a research report on Friday, August 7th. BTIG Research lifted their price objective on shares of CryoPort from $25.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, October 13th. Robert W. Baird set a $26.00 target price on shares of CryoPort in a report on Tuesday, October 13th. Finally, Needham & Company LLC upped their target price on shares of CryoPort from $19.00 to $28.00 and gave the company a "buy" rating in a research report on Friday. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.69.
Read Our Latest Research Report on CryoPort
CryoPort Company Profile
(
Free Report)
CryoPort, Inc NASDAQ: CYRX provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.
Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.
Featured Articles
Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort, Inc. (NASDAQ:CYRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CryoPort, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.
While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
